modelFimasartan

Diagram of Fimasartan

Extends from Pharmacolibrary.Drugs.ATC.C.C09CA10.

Information

name:Fimasartan
ATC code:C09CA10
route:oral
compartments:2
dosage:60mg
volume of distribution:141L
clearance:14.2L/h
other parameters in model implementation

Fimasartan is an angiotensin II receptor antagonist (ARB) used for the treatment of hypertension, helping to lower blood pressure and reduce the risk of cardiovascular events. It is approved and used in several countries, particularly in South Korea.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers following oral administration.

References

  1. Chi, YH, et al., & Kim, SL (2011). Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. American journal of cardiovascular drugs : drugs, devices, and other interventions 11(5) 335–346. DOI:10.2165/11593840-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21910510

  2. Kim, TH, et al., & Shin, BS (2015). Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. The AAPS journal 17(5) 1210–1223. DOI:10.1208/s12248-015-9764-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25990964

  3. Bulitta, JB, et al., & Shin, BS (2017). Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 107 32–44. DOI:10.1016/j.ejps.2017.06.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28599987

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)